【摘要】 脑胶质瘤是颅内最常见的原发性恶性肿瘤,具有多克隆起源、高度异质性及放化疗耐药等特性,导致患者预后极差。经典组织病理学分型往往忽视恶性肿瘤的高度异质性,难以满足肿瘤精准医疗的要求。因此,建立以经典组织病理学为基础、肿瘤标志物检测为核心的分子病理体系迫在眉睫。本文介绍了高通量技术的发展及分子生物学技术的进步,以及多维组学的脑胶质瘤分子分型及标志物的研究进展,和分子病理指导下的胶质瘤个体化治疗。更多还原

【Abstract】 The glioma is the most common and lethal malignant tumor in the central nervous system. The malignant progression and the poor prognosis could be traced to its polyclonal origin, the heterogeneity and the chemo-/radio- therapy resistance. The classical pathology is based on the morphology criteria, which could not reflect the genetic alterations and has a limited prognostic implication. It is an urgently task to construct the histology and the molecular biomarker based the detection system. With the development of the high-throughput and biological technique, great progresses have been made in the identification of the multi-omics-based classification and the detection of the biomarker, to provide a basis for the regulatory network exploration, the target discovering, the drug selection and the clinical application.更多还原